ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings
Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 股东会议事规则（2025年11月） | 2025-11-25 | Chinese | |
| 对外担保管理制度（2025年11月） | 2025-11-25 | Chinese | |
| 信息披露管理制度（2025年11月） | 2025-11-25 | Chinese | |
| 关联交易决策制度（2025年11月） | 2025-11-25 | Chinese | |
| 外部信息使用人管理制度（2025年11月） | 2025-11-25 | Chinese | |
| 年报信息披露重大差错责任追究制度（2025年11月） | 2025-11-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 35333511 | 股东会议事规则（2025年11月） | 2025-11-25 | Chinese | ||
| 35333496 | 对外担保管理制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333485 | 信息披露管理制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333471 | 关联交易决策制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333460 | 外部信息使用人管理制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333448 | 年报信息披露重大差错责任追究制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333431 | 公司章程（2025年11月） | 2025-11-25 | Chinese | ||
| 35333418 | 内幕信息知情人管理制度(2025年11月） | 2025-11-25 | Chinese | ||
| 35333411 | 总裁工作细则（2025年11月） | 2025-11-25 | Chinese | ||
| 35333400 | 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第一个解除限售期解除限售条件成就及预留授予股票第一个解除限售期解除限售条件部分成就的公告 | 2025-11-25 | Chinese | ||
| 35333391 | 独立董事提名人声明与承诺（汪律） | 2025-11-25 | Chinese | ||
| 35333378 | 关于召开2025年第三次临时股东大会的通知 | 2025-11-25 | Chinese | ||
| 35333367 | 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股票第三个解除限售期解除限售条件成就的公告 | 2025-11-25 | Chinese | ||
| 35333353 | 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第一个解除限售期解除限售条件部分未成就和抗肿瘤事业部以外获授人员预留授予股票第二个解除限售期解除限售条件未成就及回购注销部分限制性股票的公告 | 2025-11-25 | Chinese | ||
| 35333343 | 内部审计制度（2025年11月） | 2025-11-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55035/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55035 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55035 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55035 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55035}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. (id: 55035)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.